Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phototoxicity of FMX-101 4% in Healthy Volunteers
NCT04070742Phase 1Completed
- Sponsor
- Vyne Therapeutics
- Start
- Aug 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial in acne vulgaris comparing FMX-101 with Vehicle (2 arms). Primary endpoint: Post-irradiation erythema severity at 96 hours. Started Aug 2016; status: completed.
02
Drugs
minocycline
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT04070742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04070742.